Bedford, Massachusetts-based Instylla Inc, a developer of minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy, has closed $25.4 million in Series B financing. The investors included Excelestar Ventures, Catalyst Health Ventures, Amed Ventures, Ascension Ventures, Sparta Group and Incept.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: